Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Harbour BioMed

Explore full profile

Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer

Cambridge, United StatesFounded 2016Biotech & Life Sciences
Valuation $926M Market cap · 2026
Revenue $202M Latest reported FY
EBITDA $95M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibody therapeutics for oncology and immunology.

Read full description

The company develops its portfolio and pipeline through internal research and development, collaborations, and acquisitions. Its proprietary antibody technology platforms, Harbour Mice®, generate fully human monoclonal antibodies in two formats: H2L2 and heavy chain only (HCAb). The HCAb-based immune cell engagers (HBICE®) are designed to deliver tumor-killing effects that are not achievable with traditional combination therapies. The integration of Harbour Mice® with a single B cell cloning platform provides an efficient antibody discovery engine for developing next-generation therapeutic antibodies.

Source: Dealroom company data

At a glance

Founded
2016
Headquarters
Cambridge, United States
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning Harbour BioMed.

See all news

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A13 investors entered at this stage

  • Legend Capital
  • Advantech Capital
  • GIC
  • Cambridge University Endowment Fund (CUEF)
  • Vertex Holdings
  • Sovereign Wealth Funds
  • China Life Private Equity Investment
  • Zheshang Venture Capital
  • SK Group
  • Efung Capital
  • Zhejiang University Future Capital
  • Greater Bay Area Fund
  • JT New Century

Series B and later7 investors entered at this stage

  • Hudson Bay Capital Management
  • OrbiMed
  • ShenZhen GTJA Investment Group
  • Octagon Capital Partners
  • Sage Partners
  • Country Garden
  • AstraZeneca

Talent

Book a demo to see the people
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇨🇳 China76.5%
🇺🇸 United States19.8%
🇭🇰 Hong Kong1.2%
🇳🇱 Netherlands1.2%
🇬🇧 United Kingdom1.2%
5 countries shown
Web traffic by country
4.5K monthly visits
across markets
🇺🇸 United States66.7%
🇮🇳 India15.6%
🇨🇦 Canada13.3%
🇭🇰 Hong Kong4.4%
Top 4 markets shown

Patents

Estimated portfolio value
$48M

89 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Harbour BioMed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harbour BioMed on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles